
Monday, September 16, 2024 7:54:14 AM
I did some DD on BMS. At the moment they seem to have more problems with their own business and their numbers. I think the reason for this decission is more likely to find by BMS themselves than by Immatics.
My second thought was: If BMS is out Immatics could be much more attractive for M & A...
Recent IMTX News
- Immatics Announces First Quarter 2025 Financial Results and Business Update • GlobeNewswire Inc. • 05/13/2025 11:00:00 AM
- Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting • GlobeNewswire Inc. • 04/23/2025 02:00:00 PM
- Immatics Announces Full Year 2024 Financial Results and Business Update • GlobeNewswire Inc. • 03/27/2025 11:00:00 AM
- Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME • GlobeNewswire Inc. • 11/18/2024 12:00:00 PM
- Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME • GlobeNewswire Inc. • 11/08/2024 10:00:00 PM
- Immatics Announces Pricing of $150 Million Public Offering • GlobeNewswire Inc. • 10/11/2024 12:50:00 AM
- Immatics Announces Proposed $150 Million Public Offering • GlobeNewswire Inc. • 10/10/2024 11:30:00 AM
- Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial • GlobeNewswire Inc. • 10/10/2024 10:30:00 AM
- Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 • GlobeNewswire Inc. • 10/04/2024 01:00:00 PM
- Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update • GlobeNewswire Inc. • 09/16/2024 09:25:00 AM
- Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 • GlobeNewswire Inc. • 09/06/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 11:07:01 AM
- Immatics Announces Second Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 08/13/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/31/2024 11:07:40 AM
- Immatics Appoints Alise Reicin to Board of Directors • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/22/2024 08:05:27 PM
- Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024 • GlobeNewswire Inc. • 07/18/2024 01:00:00 PM
Lingerie Fighting Championships Coming to the UK for July 4 & 6 Events • BOTY • May 19, 2025 10:00 AM
VAYK Projects to Report Over $400K Q1 Revenue • VAYK • May 15, 2025 9:00 AM
Veri Medtech (VRHI) Reaches $100 Million Revenue Milestone • VRHI • May 15, 2025 8:00 AM
Cannabix Enters Sales Distribution Agreement with Australian Distributor for BreathLogix Autonomous Alcohol Breathalyzer • BLO • May 14, 2025 8:51 AM
North Bay Resources Announces Resource Estimate of 474,000 ounces at Fran Gold Project, British Columbia • NBRI • May 13, 2025 9:58 AM
UC Asset Filed for Public Offering of 8% Dividend Preferred Units • UCASU • May 12, 2025 9:55 AM